InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Targeting Blockbuster Therapeutics
The medical efficacy of cannabinoids to treat a multiplicity of maladies is no longer in doubt. Two recently published scientific studies dispelled any apprehensions about cannabis-based therapies. The highly respected New England Journal of Medicine published a peer reviewed article that proved in a controlled study that cannabidiol dramatically reduced the number of convulsive seizures in children stricken with a severe epileptic disorder (http://nnw.fm/i0X0D). The results of this study follow a comprehensive report by the National Academies of Science, Engineering, and Medicine which confirmed that cannabinoids are effective at treating chronic pain and for providing relief from nausea and vomiting related to chemo treatments. Multiple other medicinal marijuana therapies are undergoing scientific review, including two potential blockbuster therapies in development by InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) for glaucoma and epidermolysis bullosa, a devastating genetic skin disease that afflicts up to 20 million newborns in varying degrees of severity.
Utilizing its proprietary bioinformatics assessment tool, InMed’s unique research approach can expedite identification of bioactive compounds that have the potential to significantly impact specific diseases. Using comprehensive algorithms and extensive databases, the company’s exclusive computer-based program can scrutinize, analyze and identify novel cannabinoids to determine potential new drug candidates that maximize therapeutic benefit and minimize adverse effects. InMed’s unique bioinformatics assessment tool holds significant promise for a profusion of future drug discoveries.
InMed is also developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. This proprietary process will provide pharmaceutical consistency and reliability required for drug accuracy, efficacy, and safety.
With areas of research in dermatology, ocular indications, pain and inflammation, central nervous system disorders, and respiratory and metabolic diseases, InMed’s current pipeline is targeting unmet medical conditions utilizing disease-specific formulations. InMed’s INM-750 may become the first therapy to modulate disease activity and alleviate symptoms of epidermolysis bullosa, an orphan disease with no approved treatments and significant unmet medical need. InMed’s INM-085 glaucoma treatment is a multi-target, multi-mechanism of action therapy, utilizing multiple cannabinoids for optimal efficacy in treating one of the leading causes of blindness in the developed world.
InMed’s proprietary bioinformatics drug and disease screening tool, coupled with the company’s proprietary cannabinoid manufacturing system, will provide the unique ability to rapidly produce exceptional targeted results with expedited and cost effective drug development timelines.
The company’s systems and future hold such promise that Dr. Ado Muhammed, MD, DPM, MFPM, who was instrumental in leading GW Pharmaceuticals (NASDAQ: GWPH) through development and approval of one of the world’s first cannabis-based drugs, is now chief medical officer for InMed Pharmaceuticals. GW Pharmaceuticals saw its shares rise from less than $9 in 2013 to more than $100 today, and it now has a market value of more than $2.5B. With all the upside opportunity, a share price of only 30 cents and a market cap of about $34 million, InMed seems to be a real opportunity to profit from what may become the next success story in the ongoing quest to cure and mitigate disease with cannabinoid-based therapeutics.
For more information, visit the company’s website at www.InMedPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
The medical efficacy of cannabinoids to treat a multiplicity of maladies is no longer in doubt. Two recently published scientific studies dispelled any apprehensions about cannabis-based therapies. The highly respected New England Journal of Medicine published a peer reviewed article that proved in a controlled study that cannabidiol dramatically reduced the number of convulsive seizures in children stricken with a severe epileptic disorder (http://nnw.fm/i0X0D). The results of this study follow a comprehensive report by the National Academies of Science, Engineering, and Medicine which confirmed that cannabinoids are effective at treating chronic pain and for providing relief from nausea and vomiting related to chemo treatments. Multiple other medicinal marijuana therapies are undergoing scientific review, including two potential blockbuster therapies in development by InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) for glaucoma and epidermolysis bullosa, a devastating genetic skin disease that afflicts up to 20 million newborns in varying degrees of severity.
Utilizing its proprietary bioinformatics assessment tool, InMed’s unique research approach can expedite identification of bioactive compounds that have the potential to significantly impact specific diseases. Using comprehensive algorithms and extensive databases, the company’s exclusive computer-based program can scrutinize, analyze and identify novel cannabinoids to determine potential new drug candidates that maximize therapeutic benefit and minimize adverse effects. InMed’s unique bioinformatics assessment tool holds significant promise for a profusion of future drug discoveries.
InMed is also developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. This proprietary process will provide pharmaceutical consistency and reliability required for drug accuracy, efficacy, and safety.
With areas of research in dermatology, ocular indications, pain and inflammation, central nervous system disorders, and respiratory and metabolic diseases, InMed’s current pipeline is targeting unmet medical conditions utilizing disease-specific formulations. InMed’s INM-750 may become the first therapy to modulate disease activity and alleviate symptoms of epidermolysis bullosa, an orphan disease with no approved treatments and significant unmet medical need. InMed’s INM-085 glaucoma treatment is a multi-target, multi-mechanism of action therapy, utilizing multiple cannabinoids for optimal efficacy in treating one of the leading causes of blindness in the developed world.
InMed’s proprietary bioinformatics drug and disease screening tool, coupled with the company’s proprietary cannabinoid manufacturing system, will provide the unique ability to rapidly produce exceptional targeted results with expedited and cost effective drug development timelines.
The company’s systems and future hold such promise that Dr. Ado Muhammed, MD, DPM, MFPM, who was instrumental in leading GW Pharmaceuticals (NASDAQ: GWPH) through development and approval of one of the world’s first cannabis-based drugs, is now chief medical officer for InMed Pharmaceuticals. GW Pharmaceuticals saw its shares rise from less than $9 in 2013 to more than $100 today, and it now has a market value of more than $2.5B. With all the upside opportunity, a share price of only 30 cents and a market cap of about $34 million, InMed seems to be a real opportunity to profit from what may become the next success story in the ongoing quest to cure and mitigate disease with cannabinoid-based therapeutics.
For more information, visit the company’s website at www.InMedPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
